Printer Friendly
The Free Library
14,529,882 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioVisioN AG and Abbott Sign Research Agreement.


HANOVER, Germany -- German biotech company BioVisioN AG signed an agreement with Abbott, a global, broad-based health care company, to collaborate on research relating to relating to relate prepconcernant

relating to relate prepbezüglich +gen, mit Bezug auf +acc 
 the discovery of novel biomarkers for lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . According to according to
prep.
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

3.
 the agreement, BioVisioN will analyze biological samples provided by Abbott to discover tumor tumor: see neoplasm.  biomarkers. Biomarkers play an important role in new strategies for the early diagnosis and effective treatment of diseases. Under the agreement, BioVisioN will receive research payments and, if successful, milestones and royalty payments.

Dr. Rainer Voegeli, Chief Business Officer of BioVisioN AG, was very pleased with the closing of the agreement: "Our early activities in the area of proteomics and peptidomics are now paying off. We are the world leader in peptide biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term.

Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery.
 with our patent protected technologies. We are proud that Abbott has chosen us as a partner."

BioVisioN AG specializes in the identification of disease-relevant peptides and proteins using Peptidomics and Differential Peptide Display. The company was founded in 1997 and today employs 45 people. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organization.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 9, 2005
Words:184
Previous Article:Ameritrade Reports Monthly Metrics.
Next Article:Working Together with QuarkXPress 7: Quark Emphasizes Openness and Collaboration in the Next Release of the Award-Winning Publishing Software.



Related Articles
E-MARKETS -- PROVIDING BUSINESS SOLUTIONS FOR AGRIBUSINESSES.(E-Markets Inc.)(Brief Article)
AG stock index.(comparison of stock prices at close of market on 11/30/01 and 12/31/01)(Statistical Data Included)(Illustration)
AG stock index.
Ag stock index.(agricultural related industry stock index)
CAMBRIDGE ANTIBODY TECHNOLOGY/AMGEN RESTRUCTURE AGREEMENT.
ABBOTT/EUROPROTEOME TO DEVELOP BREAST CANCER DIAGNOSTIC TESTS.
Calendar.(Calendar)
Stock price at close of market.(AG STOCK INDEX)(Illustration)
BIOVITRIM/SANTHERA SIGN PACT FOR DEVELOPING DPP-IV.
DIGILAB'S PREP SERVICES USED FOR DIABETES RESEARCH.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles